Journal List > Cancer Res Treat > v.48(2) > 1153402

TOOLS
Oh, Won, Jung, Kong, Cho, Lee, Lee, Lee, and The Community of Population-Based Regional Cancer Registries: Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013
Special Article

Cancer Res Treat 2016;48(2):436-450.

Published online: 3 March 2016

DOI: https://doi.org/10.4143/crt.2016.089

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013

Chang-Mo Oh, MD, PhD1, 2, Young-Joo Won, PhD1, 2, 3, Kyu-Won Jung, MS1, 2, Hyun-Joo Kong, MS1, 2, Hyunsoon Cho, PhD1, 2, 3, Jong-Keun Lee, MD, PhD1, 2, Duk Hyoung Lee, MD, PhD2, 3, Kang Hyun Lee, MD, PhD1; The Community of Population-Based Regional Cancer Registries*

1The Korea Central Cancer Registry, National Cancer Center, Goyang, Korea

2National Cancer Control Institute, National Cancer Center, Goyang, Korea

3Department of Cancer Control and Policy, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea

Correspondence: Young-Joo Won, PhD  The Korea Central Cancer Registry, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea  Tel: 82-31-920-2015 Fax: 82-31-920-2179 E-mail: astra67@ncc.re.kr

Received 29 February 2016       Accepted 2 March 2016

Copyright © 2016 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose:

This study described the 2013 nationwide cancer statistics in Korea, including cancer incidence, survival, prevalence, and mortality.

Materials and Methods:

Cancer incidence data from 1999-2013 were obtained from Korea National Cancer Incidence Database and followed until December 31, 2014. Mortality data from 1983-2013 were obtained from Statistics Korea. The prevalence was defined as the number of cancer patients alive on January 1, 2014 among all cancer patients diagnosed since 1999. Crude, and age-standardized and 5-year relative survival rates were also calculated.

Results:

In 2013, a total of 225,343 and 75,334 Koreans were newly diagnosed and died from cancer, respectively. The age-standardized rates for cancer incidence and mortality in 2013 were 290.5 and 87.9 per 100,000, respectively. The age-standardized cancer incidence rate increased 3.1% annually between 1999 and 2013. However, the overall cancer incidence rates have decreased slightly in recent years (2011 to 2013). The age-standardized rate for all-cancer mortality has decreased 2.7% annually since 2002. Overall, the 5-year relative survival rate for people diagnosed with cancer between 2009 and 2013 was 69.4%, which represents an improved survival rate as compared with 41.2% for people diagnosed between 1993 and 1995.

Conclusion:

Age-standardized cancer incidence rates have decreased between 2011 and 2013; mortality rates have also declined since 2002, while 5-year survival rates have improved remarkably from 1993-1995 to 2009-2013 in Korea.

Keywords: Incidence, Mortality, Survival, Prevalence, Neoplasms, Korea

Introduction

Cancer is a major life-threatening disease worldwide. GLOBOCAN 2012 estimated that approximately 14.1 million patients were newly diagnosed with cancer and 8.2 million people died from cancer [1]. The global burden of cancer is expected to grow rapidly due to population growth and aging [2].
In Korea, cancer accounts for one in four deaths (27.6%) and more than 200,000 new cancer cases were diagnosed in 2012 [3]. Cancer incidence and deaths are expected to increase with increasing population aging and westernized lifestyles [4]. In addition, the economic burden of cancer in Korea increased about 1.8-fold, from $11,424 to $20,858 million, between 2000 and 2010 [5].
In this context, cancer statistics are the most important indicator to assess the national cancer burden and establish cancer prevention and control strategies. This article aims to provide nationwide cancer statistics including cancer incidence, survival, prevalence, and mortality in 2013.

Materials and Methods

1. Data sources

The Korea Central Cancer Registry (KCCR) was established by the Ministry of Health and Welfare in 1980. Until 1998, the KCCR registered cancer cases from hospitals in order to determine cancer incidence, with increasing coverage. Since 1999, the KCCR has collected cancer incidence data nationwide by integrating a hospital-based KCCR database with data from regional cancer registry programs. The KCCR currently provides the nationwide cancer incidence, survival, and prevalence statistics annually. KCCR has been described in more detail elsewhere [6].
The KCCR built the Korea National Cancer Incidence Database (KNCI DB) from hospitals, 11 population-based registries, site-specific cancer registries, and additional medical chart review. The KNCI DB includes patient case information including age, sex, region, date of birth, date of diagnosis, primary cancer site, histological type, most valid diagnostic method, and stage. The completeness of cancer incidence data for 2013 was estimated to be 97.8% based on the method proposed by Ajiki et al. [7]. Mid-year population and cancer mortality data from 1983 to 2013 were obtained from Statistics Korea (http://kosis.kr) [8]. To ascertain vital status and calculate survival and prevalence, the KNCI DB was linked to mortality data.

2. Classification

All incident cancer cases were collected and registered according to the International Classification of Diseases for Oncology, 3rd edition [9]. The all cancer cases were reported according to the International Classification of Diseases, 10th edition (ICD-10) [10] and categorized into 24 cancer types.

3. Statistical analyses

Rates were expressed as crude and age-standardized rates (CR and ASR, respectively) per 100,000 individuals. The crude rate was calculated as the total number of incidence/mortality cases divided by the mid-year population of the specified years. The sum of the expected age-specific rates was obtained by multiplying the age-specific incidence rates among study population by the proportion of population in the corresponding age-specific groups among standard population. Next, the age-standardized incidence rates per 100,000 people were calculated as the sums of the expected age-specific rates divided by the sum of the standard population [11]. We used Segi’s world standard population to calculate the age-standardized rates [12]. Age-specific rates were also calculated for given age groups. The cumulative risk of developing cancer from birth to life expectancy were calculated using cumulative rates; that is, the sum of the age-specific rates from birth to life expectancy, as follows [13]:
Cumulative risk of developing cancer from birth to life expectancy=100×(1-e-cumulative rate100)
Trends in incidence/mortality rates were summarized as annual percentage change (APC). APC is the average percentage change of rates and is calculated as follows [11]:
APC=Ry+1-RyRy×100=(eb1-1)×100
, where log(Ry)=b0+b1y,
log(Ry) is the natural log transformed age standardized rates.
y=year, b0=intercept, b1=slope
The survival duration for each cancer case was determined as the interval between the date of initial diagnosis and the date of death, date of loss of follow-up, or closing date for follow-up (December 31, 2014). Relative survival rates were calculated using the Ederer II method [14] with some minor corrections, based on an algorithm by Paul Dickman [15]. The 5-year relative survival rates were calculated as the ratios of the observed survival of the cancer patients to the expected survival of the general population, which was derived from the standard life table provided by Statistics Korea. Trends in 5-year relative survival rates were evaluated as percentage differences in 5-year relative survival rates from 1993-1995 and 2009-2013.
Prevalent cases were defined as the number of cancer patients alive on January 1, 2014 among all cancer patients diagnosed between 1999 and 2013. Limited-duration prevalences were calculated using SEER*Stat software to calculate 1-, 3-, and 5-year prevalent cases.
P-values less than 0.05 were considered statistically significant. SEER*Stat 8.2.1 (National Cancer Institute, Bethesda, MD) and SAS 9.3 (SAS Institute Inc., Cary, NC) were used to calculate the incidence, mortality, survival, and prevalence and to perform the statistical analyses.

Selected Findings

1. Incidence

A total of 225,343 cases were newly diagnosed with cancer during the study period (Table 1). Of these cases, 113,744 (50.5%) were men and 111,599 cases (49.5%) were women. Thyroid cancer was the most commonly diagnosed cancer in 2013, and followed by stomach, colorectal, lung, and breast cancer in 2013. The overall cumulative risk of developing cancer from birth to life expectancy was 36.6%. However, the cumulative risk of developing cancer from birth to life expectancy was higher in men (38.3%) than in women (35.0%).
The total CR and ASR for overall cancer incidence in 2013 were 445.7 and 290.5 per 100,000, respectively (Table 2). According to sex, CRs for all sites combined were 449.9 per 100,000 in men and 441.5 per 100,000 in women. The ASRs were 316.5 and 281.8 per 100,000 in men and women, respectively. Stomach cancer (CR, 80.2 per 100,000) was the most common cancer in men, followed by colorectal (CR, 65.6 per 100,000), lung (CR, 64.0 per 100,000), liver (CR, 47.9 per 100,000), and prostate cancer (CR, 37.6 per 100,000). These five cancers accounted for 65.6% of newly diagnosed cancer in men during the study period. In contrast, thyroid cancer (CR, 134.9 per 100,000) was the most common cancer among women, followed by breast (CR, 68.2 per 100,000), colorectal (CR, 43.6 per 100,000), stomach (CR, 39.2 per 100,000), and lung cancer (CR, 27.7 per 100,000). These five cancers accounted for 71.0% of cases in women.

2. Mortality

In 2013, cancer was the most common leading cause of death in Korea (Table 3). The total number of deaths from cancer was 75,334 in 2013, accounting for 28.3% of all deaths (Table 3). According to sex, 62.5% and 37.5% of cancer deaths occurred in men and women, respectively (Table 1).
The total CR and ASR for cancer deaths were 149.0 and 87.9 per 100,000, respectively, in 2013 (Table 4). The total CR and ASR for cancer deaths per 100,000 were higher among men (ASR, 130.1) than in women (ASR, 57.5).
According to the cancer sites, lung cancer (CR, 49.5 per 100,000) was the leading cause of death in men, followed by liver (CR, 33.3 per 100,000), stomach (CR, 23.7 per 100,000), colorectal (CR, 18.4 per 100,000), and pancreatic cancer (CR, 10.3 per 100,000). The top five causes of deaths from cancer in women included lung (CR, 18.4 per 100,000), colorectal (CR, 14.0 per 100,000), stomach (CR, 12.6 per 100,000), liver (CR, 11.8 per 100,000), and breast cancer (CR, 8.8 per 100,000)

3. Trends in cancer incidence and mortality rates

The trends in overall cancer incidence and mortality rates by sex are shown in Fig. 1. The ASR for all-cancer incidence increased 3.1% annually from 1999 to 2013 (Table 5, Fig. 1). However, in recent years, ASR for all-cancer incidence has decreased slightly, from 303.8 per 100,000 in 2011 to 290.5 per 100,000 in 2013 (APC, –2.1%). In contrast, ASR for all-cancer mortality has decreased 2.7% annually from 2002 to 2013 (Fig. 1).
The ASR for all-cancer incidence in women (APC, 5.1%; 95% confidence interval [CI], 4.6 to 5.6) has increased more rapidly than that in men (APC, 1.3%; 95% CI, 1.0 to 1.6) (Tables 6 and 7) since 1999, whereas ASR for all-cancer mortality in men (APC, –3.1%; 95% CI, –3.3 to –2.8) has decreased faster than that in women (APC, –2.2%; 95% CI, –2.5 to –1.9) since 2002 (Fig. 1).

4. Trends in cancer incidence and mortality rates by common cancer sites

Between 1999 and 2013, ASR for thyroid cancer incidence has been most notably increased in both men (APC, 22.7%) and women (APC, 20.6%) (Tables 6 and 7). Among men, the age-standardized incidence rates of prostate (APC, 10.7%) and colorectal cancer (APC, 5.0%) have increased from 1999 to 2013, while the age-standardized incidence rates of liver (APC, –2.2%), lung (APC, –1.0%), and stomach cancer (APC, –0.8%) have decreased from 1999 to 2013 (Table 6, Fig. 2). Among women, the age-standardized incidence rates of breast (APC, 5.9%), colorectal (APC, 3.7%), and lung (APC, 1.7%) have increased from 1999 to 2013 (Table 7). However, the age-standardized incidence rates of cervical (APC, –3.9%), liver (APC, –1.8%), and stomach cancer (APC, –0.7%) in women have decreased from 1999 to 2013.
The age-standardized mortality rate of stomach cancer has decreased continuously in both sexes (Fig. 3). Although the age-standardized mortality rate of colorectal cancer increased from 1983 to 2003, the mortality rate of colorectal cancer has leveled off since 2003 in men. For women, the age-standardized mortality of colorectal cancer increased from 1983 to 2004, but the mortality rate has subsequently decreased. For both sexes, the age-standardized mortality of lung cancer increased from 1983 to 2002, and the mortality rates for lung cancer decreased. The mortality rates for uterine cancer in women and liver cancer in both sexes have continuously decreased since the mid-1990s. However, the breast cancer mortality rate in women and the prostate cancer mortality rate in men showed increasing trends during the observation period (1983-2013).

5. Age-specific incidence rates

According to age group, leukemia was the most commonly diagnosed cancer among children between 0-14 years of age, while thyroid cancer was the most common cancer among adolescents and young adults between 15 and 34 years of age (Table 8). For men, the incidence rate of cancer increased with age (Fig. 4A). Stomach cancer was the most commonly diagnosed cancer among men aged 35 and 64 years old, while lung cancer was the most common among elderly men aged ≥ 65 years. In contrast, thyroid cancer was most commonly diagnosed among women aged 35 and 64 years, while colorectal cancer was most common among elderly women aged ≥ 65 years. Thyroid and breast cancer showed inverted U-shaped incidence rates by age (Fig. 4B).

6. Survival rates

The 5-year relative survival rates for all cancer combined improved remarkably in both sexes, from 41.2% in 1993-1995 to 69.4% in 2009-2013 (Table 9, Fig. 5A). After excluding thyroid cancer, the 5-year relative survival rates for all cancer still increased from 1993-1995 to 2009-2013 (Fig. 5B).
The 5-year relative survival rate in 2009-2013 for all cancer combined was 61.0% in men and 77.7% in women, respectively. The 5-year relative survival rate for thyroid cancer was over 100%, while the 5-year relative survival rates for testis, prostate, and breast cancer were over 90% in 2009-2013 for both sexes, respectively. However, the 5-year relative survival rate for pancreatic cancer was only 9.4% in both sexes in 2009-2013.
When compared to the 5-year relative survival rate for 1993-1995, prostate cancer diagnosed from 2009 to 2013 showed the most outstanding improvement, followed by stomach cancer, leukemia, ‘lip, oral cavity, and pharynx’ and colorectal cancer in men. Among women, stomach cancer diagnosed during 2009-2013 showed the greatest improvement in 5-year relative survival rates compared to those between 1993 and 1995, followed by leukemia, non-Hodgkin’s lymphoma, colorectal cancer, and kidney cancer.

7. Prevalence rates

A total of 1,370,049 cancer prevalent cases were identified on January 1, 2014 (Table 1). Of these cases, 603,524 (44.1%) were men and 766,525 (55.9%) were women. The crude and age-standardized prevalence rates for cancer overall were 2,709.8 per 100,000 individuals and 1,772.4 per 100,000 individuals for both sexes, respectively, in 2013 (Table 10). Among men, the crude and age-standardized prevalence rates for cancer overall were 2,387.1 and 1,683.6 per 100,000 individuals, respectively. Among women the rates for cancer overall were 3,032.6 and 1,944.3 per 100,000 individuals, respectively.
The five most common cancers for men were stomach (CR, 589.0 per 100,000), colorectal (CR, 449.1 per 100,000), prostate (CR, 220.5 per 100,000), thyroid (CR, 194.3 per 100,000), and liver cancer (CR, 163.0 per 100,000). In contrast, thyroid cancer was most common in women (CR, 995.9 per 100,000), followed by breast (CR, 579.3 per 100,000), colorectal (CR, 302.8 per 100,000), stomach (CR, 298.4 per 100,000), and cervix uteri cancer (CR, 181.9 per 100,000).
Analysis of the time period after cancer diagnosis revealed that thyroid cancer (23.2%) was the most prevalent cancer within 2 years after cancer diagnosis, followed by stomach (13.9%) and colorectal cancer (13.3%) (Fig. 6). Thyroid cancer (26.2%) was most prevalent for 2-5 years, followed by stomach (15.4%) and colorectal cancer (14.0%). After 5 years, stomach cancer (18.6%) was the most prevalent cancer, followed by thyroid (18.1%) and colorectal cancer (14.1%).

Notes

*The Community of Population-Based Regional Cancer Registries

Chang-Hoon Kim (Busan Cancer Registry, Pusan National University Hospital), Cheol-In Yoo (Ulsan Cancer Registry, Ulsan University Hospital), Heon Kim (Chungbuk Cancer Registry, Chungbuk National University Hospital), Hae-Sung Nam (Daejeon/Chungnam Cancer Registry, Chungnam National University Hospital), Jung-Sik Huh (Jeju Cancer Registry, Jeju National University Hospital), Jung-Ho Youm (Chonbuk Cancer Registry, Chonbuk National University Hospital), Moo-Kyung Oh (Kangwon Cancer Registry, Kangwon National University Hospital), Nam-Soo Hong (Daegu/Gyeongbuk Cancer Registry, Kyungpook National University Medical Center), Sun-Seog Kweon (Gwangju/Chonnam Cancer Registry, Chonnam National University Hwasun Hospital), Woo-Chul Kim (Incheon Cancer Registry, Inha University Hospital), Yune-Sik Kang (Gyeongnam Cancer Registry, Gyeongsang National University Hospital)

Conflict of interest relevant to this article was not reported.

ACKNOWLEDGMENTS

This work was supported by a research grant from the National Cancer Center (No. 1610200), Republic of Korea. The authors are indebted to Korea Central Cancer Registry (KCCR)-affiliated hospitals, non-KCCR-affiliated hospitals, the National Health Insurance Service and Statistics Korea for data collection.

References

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer;2013. [cited 2016 Jan 28]. Available from: http://globocan.iarc.fr.
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385:117–71.
3. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015; 47:127–41.
crossref
4. Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee DH, et al. Prediction of cancer incidence and mortality in Korea, 2015. Cancer Res Treat. 2015; 47:142–8.
crossref
5. Lee KS, Chang HS, Lee SM, Park EC. Economic burden of cancer in Korea during 2000-2010. Cancer Res Treat. 2015; 47:387–98.
crossref
6. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005; 37:325–31.
crossref
7. Ajiki W, Tsukuma H, Oshima A. Index for evaluating completeness of registration in population-based cancer registries and estimation of registration rate at the Osaka Cancer Registry between 1966 and 1992 using this index. Nihon Koshu Eisei Zasshi. 1998; 45:1011–7.
8. Statistics Korea [Internet]. Daejeon: Statistics Korea;2015. [cited 2015 Jan 28]. Available from: http://kosis.kr.
9. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization;2000.
10. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. Geneva: World Health Organization;1994.
11. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER cancer statistics review, 1975-2012 [Internet]. Bethesda, MD: National Cancer Institute;2013. [cited 2015 Jan 28]. Available from: http://seer.cancer.gov/csr/1975_2012/.
12. Segi M. Cancer mortality for selected sites in 24 countries (1950-1957). Sendai: Tohoku University School of Medicine;1960.
13. Day NE. Cumulative rates and cumulative risk. In : Muir C, Waterhouse J, Mack T, Powell J, Whelan S, editors. Cancer incidence in five continents. Vol. V. IARC Scientific Publications No. 88. Lyon: International Agency for Research on Cancer;787. p. 1011–9.
14. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note, No. 10. Bethesda, MD: National Cancer Institute;1959.
15. Paul Dickman [Internet]. Stockholm: PaulDickman.com;2016. [cited 2016 Jan 14]. Available from: http//www.pauldickman.com.

Fig. 1.
Annual age-standardized cancer incidence and death rates by sex for all sites from 1983 to 2013 in Korea. Age standardization was based on the Segi’s world standard population.
crt-2016-089f1.tif
Fig. 2.
Trends in age-standardized incidences of selected cancers by sex from 1999 to 2013 in Korea. (A) Men. (B) Women. Age standardization was based on the Segi’s world standard population.
crt-2016-089f2.tif
Fig. 3.
Annual age-standardized cancer mortalities of selected cancers by sex from 1983 to 2013 in Korea. (A) Men. (B) Women. Age standardization was based on the Segi’s world standard population.
crt-2016-089f3.tif
Fig. 4.
Age-specific incidence rates of common cancers for 2013 in Korea. (A) Men. (B) Women.
crt-2016-089f4.tif
Fig. 5.
Trends in relative survival by year of diagnosis from 1999 to 2013. (A) All sites for both sexes. (B) All sites except thyroid cancer for both sexes.
crt-2016-089f5.tif
Fig. 6.
Prevalence of common cancer sites by time period after cancer diagnosis. Prevalent cases were defined as the number of cancer patients alive on January 1, 2014 among all cancer patients diagnosed between 1999 and 2013.
crt-2016-089f6.tif
Table 1.
Cancer incidence, deaths and prevalence by sex in Korea, 2013
Site/Type New cases
 Deaths
 Prevalent casesa)
Both sexes Male Female Both sexes Male Female Both sexes Male Female
All sites 225,343 113,744 111,599 75,334 47,079 28,255 1,370,049 603,524 766,525
Lip, oral cavity, and pharynx 3,041 2,181 860 1,078 821 257 18,539 12,476 6,063
Esophagus 2,382 2,186 196 1,448 1,320 128 8,090 7,321 769
Stomach 30,184 20,266 9,918 9,180 5,995 3,185 224,352 148,926 75,426
Colon and rectum 27,618 16,593 11,025 8,199 4,659 3,540 190,094 113,547 76,547
Liver 16,192 12,105 4,087 11,405 8,421 2,984 55,049 41,203 13,846
Gallbladderb) 5,283 2,707 2,576 3,783 1,874 1,909 16,021 8,195 7,826
Pancreas 5,511 2,982 2,529 4,831 2,615 2,216 7,757 4,185 3,572
Larynx 1,196 1,116 80 403 369 34 9,149 8,592 557
Lung 23,177 16,171 7,006 17,177 12,519 4,658 58,653 37,399 21,254
Breast 17,292 61 17,231 2,244 13 2,231 147,012 596 146,416
Cervix uteri 3,633 - 3,633 892 - 892 45,989 - 45,989
Corpus uteri 2,212 - 2,212 248 - 248 17,053 - 17,053
Ovary 2,236 - 2,236 1,038 - 1,038 15,362 - 15,362
Prostate 9,515 9,515 - 1,629 1,629 - 55,756 55,756 -
Testis 254 254 - 19 19 - 2,440 2,440 -
Kidney 4,333 2,992 1,341 937 664 273 29,069 19,621 9,448
Bladder 3,762 3,025 737 1,280 975 305 27,440 22,360 5,080
Brain and CNS 1,813 941 872 1,196 625 571 9,302 4,828 4,474
Thyroid 42,541 8,454 34,087 393 120 273 300,851 49,119 251,732
Hodgkin lymphoma 262 169 93 63 41 22 2,194 1,401 793
Non-Hodgkin lymphoma 4,828 2,668 2,160 1,581 929 652 29,347 15,797 13,550
Multiple myeloma 1,327 694 633 804 437 367 4,325 2,256 2,069
Leukemia 3,011 1,716 1,295 1,593 945 648 16,309 9,002 7,307
Other and ill-defined 13,740 6,948 6,792 3,913 2,089 1,824 79,896 38,504 41,392

CNS, central nervous system.

a) Limited-duration prevalent cases on January 1, 2014. These are patients who were diagnosed between January 1, 1999 and December 31, 2013 and who were alive on January 1, 2014. Multiple primary cancer cases were counted multiple times,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 2.
Crude and age-standardized cancer incidence rates by sex in Korea, 2013
Site/Type Crude incidence rate per 100,000
 Age-standardized incidence rate per 100,000a)
Both sexes Male Female Both sexes Male Female
All sites 445.7 449.9 441.5 290.5 316.5 281.8
Lip, oral cavity, and pharynx 6.0 8.6 3.4 4.0 6.0 2.2
Esophagus 4.7 8.6 0.8 2.9 6.0 0.4
Stomach 59.7 80.2 39.2 37.4 55.3 22.4
Colon and rectum 54.6 65.6 43.6 34.0 45.6 24.4
Liver 32.0 47.9 16.2 20.2 32.8 9.0
Gallbladderb) 10.4 10.7 10.2 6.1 7.4 5.0
Pancreas 10.9 11.8 10.0 6.6 8.2 5.2
Larynx 2.4 4.4 0.3 1.5 3.1 0.2
Lung 45.8 64.0 27.7 27.4 44.2 14.9
Breast 34.2 0.2 68.2 23.0 0.2 45.7
Cervix uteri 7.2 - 14.4 4.8 - 9.5
Corpus uteri 4.4 - 8.8 2.9 - 5.8
Ovary 4.4 - 8.8 3.1 - 6.0
Prostate 18.8 37.6 - 11.4 26.2 -
Testis 0.5 1.0 - 0.5 1.0 -
Kidney 8.6 11.8 5.3 5.7 8.3 3.4
Bladder 7.4 12.0 2.9 4.4 8.3 1.4
Brain and CNS 3.6 3.7 3.4 2.9 3.2 2.7
Thyroid 84.1 33.4 134.9 60.1 24.0 96.6
Hodgkin lymphoma 0.5 0.7 0.4 0.4 0.6 0.3
Non-Hodgkin lymphoma 9.5 10.6 8.5 6.7 8.0 5.6
Multiple myeloma 2.6 2.7 2.5 1.6 1.9 1.4
Leukemia 6.0 6.8 5.1 5.0 6.0 4.2
Other and ill-defined 27.2 27.5 26.9 17.8 20.5 15.6

CNS, central nervous system.

a) Age-adjusted using the world standard population,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 3.
The top 10 leading causes of death in Korea, 2013
Rank Cause of death No. of deaths Percentage of all deaths Age-standardized death rate per 100,000a)
All causes 266,257 100.0 309.4
1 Cancer 75,334 28.3 87.9
2 Cerebrovascular disease 25,447 9.6 27.0
3 Heart disease 25,365 9.5 27.9
4 Intentional self-harm (suicide) 14,427 5.4 20.3
5 Diabetes mellitus 10,888 4.1 11.6
6 Pneumonia 10,809 4.1 11.2
7 Chronic lower respiratory diseases 7,074 2.7 7.3
8 Disease of liver 6,665 2.5 8.3
9 Transport accidents 6,028 2.3 8.7
10 Hypertensive diseases 4,732 1.8 4.9
Others 79,488 29.9 94.4

Source: Mortality Data, 2013, Statistics Korea [8].

a) Age-adjusted using the world standard population.

Table 4.
Crude and age-standardized cancer mortality rates by sex in Korea, 2013
Site/Type Crude mortality rate per 100,000
 Age-standardized mortality rate per 100,000a)
Both sexes Male Female Both sexes Male Female
All sites 149.0 186.2 111.8 87.9 130.1 57.5
Lip, oral cavity, and pharynx 2.1 3.2 1.0 1.3 2.3 0.5
Esophagus 2.9 5.2 0.5 1.7 3.6 0.3
Stomach 18.2 23.7 12.6 10.5 16.4 6.1
Colon and rectum 16.2 18.4 14.0 9.3 12.9 6.7
Liver 22.6 33.3 11.8 13.8 22.9 6.1
Gallbladderb) 7.5 7.4 7.6 4.2 5.2 3.5
Pancreas 9.6 10.3 8.8 5.6 7.2 4.4
Larynx 0.8 1.5 0.1 0.4 1.0 0.1
Lung 34.0 49.5 18.4 19.3 34.0 8.8
Breast 4.4 0.1 8.8 2.9 0.0 5.6
Cervix uteri 1.8 - 3.5 1.1 - 1.9
Corpus uteri 0.5 - 1.0 0.3 - 0.6
Ovary 2.1 - 4.1 1.3 - 2.4
Prostate 3.2 6.4 - 1.7 4.8 -
Testis 0.0 0.1 - 0.0 0.1 -
Kidney 1.9 2.6 1.1 1.1 1.8 0.5
Bladder 2.5 3.9 1.2 1.4 2.8 0.5
Brain and CNS 2.4 2.5 2.3 1.7 2.0 1.5
Thyroid 0.8 0.5 1.1 0.4 0.3 0.5
Hodgkin lymphoma 0.1 0.2 0.1 0.1 0.1 0.1
Non-Hodgkin lymphoma 3.1 3.7 2.6 1.9 2.6 1.3
Multiple myeloma 1.6 1.7 1.5 0.9 1.2 0.8
Leukemia 3.2 3.7 2.6 2.2 2.9 1.6
Other and ill-defined 7.7 8.3 7.2 4.7 6.0 3.8

CNS, central nervous system.

a) Age-adjusted using the world standard population,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 5.
Trends in cancer incidence rates for both sexes from 1999 to 2013 in Korea
Site/Type Year
 APC
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
All sites 210.5 205.1 216.7 220.1 227.9 235.1 247.9 252.2 263.5 276.1 286.9 293.5 303.8 301.7 290.5 3.1a)
Lip, oral cavity, and pharynx 3.6 4.4 3.6 3.7 3.8 3.8 3.8 3.8 3.9 4.0 3.8 4.0 4.1 4.0 4.0 0.4
Esophagus 4.1 3.7 3.9 3.8 3.6 3.6 3.5 3.4 3.3 3.3 3.1 3.1 3.0 3.0 2.9 –2.2a)
Stomach 43.6 42.3 44.0 43.6 43.3 41.2 44.4 42.8 41.8 42.6 43.4 42.5 42.8 40.1 37.4 -0.6
Colon and rectum 20.4 21.0 22.9 24.7 26.9 28.6 31.0 32.5 33.8 34.9 36.9 36.9 38.3 37.7 34.0 4.6a)
Liver 27.9 26.7 27.3 26.5 25.7 25.6 25.8 24.6 24.4 24.1 23.5 22.8 22.5 21.2 20.2 –2.0a)
Gallbladderb) 6.5 6.4 6.7 6.7 6.7 6.9 7.1 6.6 6.6 6.4 6.8 6.6 6.4 6.3 6.1 –0.3
Pancreas 5.6 5.5 5.5 5.8 5.9 6.0 6.3 6.2 6.3 6.4 6.3 6.4 6.7 6.8 6.6 1.5a)
Larynx 2.3 2.2 2.4 2.2 2.1 1.9 2.0 1.8 1.8 1.7 1.7 1.6 1.5 1.4 1.5 –3.5a)
Lung 28.5 27.7 28.3 28.5 27.9 28.8 29.0 28.7 28.4 28.2 28.3 28.6 28.7 27.7 27.4 –0.1
Breast 10.7 10.8 12.7 13.9 14.3 15.0 16.3 17.0 18.1 18.9 19.7 20.7 22.3 22.7 23.0 5.8a)
Cervix uteri 8.5 7.9 8.3 7.7 7.4 6.9 6.5 6.4 5.7 5.9 5.5 5.6 5.2 4.9 4.8 –4.1a)
Corpus uteri 1.4 1.3 1.5 1.7 1.9 1.9 2.0 2.1 2.2 2.4 2.6 2.6 2.7 2.7 2.9 5.6a)
Ovary 2.7 2.5 2.5 2.6 2.7 2.7 2.8 2.8 3.1 2.9 2.8 3.0 3.0 3.1 3.1 1.4a)
Prostate 3.1 2.7 3.6 3.9 4.8 6.0 6.3 7.3 8.6 9.8 10.6 11.0 11.9 11.7 11.4 12.0a)
Testis 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.5 4.6a)
Kidney 3.0 2.9 3.3 3.4 3.5 3.7 4.1 4.4 4.8 5.1 5.2 5.3 5.6 5.6 5.7 5.5a)
Bladder 4.6 4.6 4.9 4.7 5.1 5.1 5.1 4.9 5.0 4.8 4.6 4.7 4.7 4.4 4.4 –0.5
Brain and CNS 2.9 2.8 2.8 2.6 2.9 2.9 3.0 2.9 3.1 3.1 3.0 3.1 2.7 2.9 2.9 0.4
Thyroid 6.3 6.1 7.9 9.5 12.8 17.3 20.7 25.5 32.9 41.4 48.2 53.7 59.2 63.2 60.1 20.8a)
Hodgkin lymphoma 0.2 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.4 0.4 0.4 0.4 0.5 0.5 0.4 4.7a)
Non-Hodgkin lymphoma 4.5 4.2 4.5 4.6 5.0 5.3 5.3 5.5 5.6 5.7 6.2 6.2 6.6 6.7 6.7 3.5a)
Multiple myeloma 1.0 1.0 1.1 1.1 1.1 1.2 1.3 1.3 1.4 1.4 1.5 1.5 1.4 1.6 1.6 3.6a)
Leukemia 4.7 4.3 4.7 4.8 4.8 4.8 4.7 4.9 4.9 5.0 5.1 5.0 5.2 5.0 5.0 0.9a)
Other and ill-defined 14.3 13.5 13.9 13.5 15.2 15.3 16.2 16.2 17.3 17.1 17.2 17.6 18.3 17.9 17.8 2.3a)

APC was calculated using age-standardized incidence data based on the world standard population. APC, annual percentage change; CNS, central nervous system.

a) Significantly different from zero (p < 0.05),

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 6.
Trends in cancer incidence rates in men from 1999 to 2013 in Korea
Site/Type Year
 APC
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
All sites 285.0 276.7 288.3 290.0 295.1 299.6 311.4 310.3 317.1 324.2 330.9 332.0 337.2 329.1 316.5 1.3a)
Lip, oral cavity, and pharynx 6.1 7.1 6.0 6.2 6.5 6.2 6.1 6.2 6.3 6.5 6.1 6.1 6.4 6.2 6.0 –0.2
Esophagus 8.8 8.0 8.3 8.2 7.7 7.7 7.6 7.2 7.0 7.0 6.6 6.5 6.3 6.1 6.0 –2.6a)
Stomach 66.2 65.0 67.2 66.6 66.0 62.3 66.9 65.3 63.1 64.5 65.0 63.4 63.8 59.6 55.3 –0.8a)
Colon and rectum 26.2 27.2 29.6 32.9 35.3 38.0 41.2 43.3 45.3 47.0 50.0 50.1 52.0 50.4 45.6 5.0a)
Liver 46.8 44.7 45.1 43.9 42.3 42.1 42.6 40.3 39.8 39.5 38.2 36.9 36.1 34.5 32.8 –2.2a)
Gallbladderb) 8.1 7.8 8.2 8.1 7.8 8.4 8.7 8.1 7.9 7.6 8.1 8.2 7.7 7.6 7.4 –0.4
Pancreas 7.8 7.6 7.6 7.9 7.7 8.0 8.3 8.0 8.2 8.4 8.1 8.1 8.6 8.5 8.2 0.7a)
Larynx 4.9 4.5 5.1 4.7 4.5 4.1 4.3 3.8 3.8 3.5 3.6 3.4 3.2 3.0 3.1 –3.6a)
Lung 51.4 49.8 51.1 51.0 50.0 50.8 50.9 49.2 48.8 47.7 47.5 47.5 46.7 44.7 44.2 –1.0a)
Breast 0.2 0.3 0.2 0.3 0.2 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.2 0.2 –1.4
Prostate 8.4 7.2 9.5 10.1 12.5 15.2 15.8 18.0 20.9 23.5 25.3 26.1 27.7 27.3 26.2 10.7a)
Testis 0.6 0.5 0.6 0.6 0.6 0.6 0.6 0.7 0.7 0.7 0.8 0.8 0.9 0.9 1.0 4.5a)
Kidney 4.5 4.4 4.9 5.0 5.2 5.5 6.0 6.5 7.1 7.5 7.6 8.0 8.1 8.3 8.3 5.2a)
Bladder 9.0 9.0 9.4 9.0 9.7 9.8 9.8 9.6 9.5 9.2 8.7 8.9 8.9 8.3 8.3 –0.7a)
Brain and CNS 3.2 3.1 3.1 2.9 3.3 3.3 3.3 3.2 3.4 3.4 3.5 3.5 3.0 3.3 3.2 0.5
Thyroid 2.1 1.9 2.4 2.7 3.7 4.8 5.9 7.5 10.0 13.3 15.6 18.6 20.4 23.3 24.0 22.7a)
Hodgkin lymphoma 0.4 0.4 0.4 0.3 0.4 0.5 0.4 0.4 0.5 0.5 0.5 0.6 0.6 0.6 0.6 3.9a)
Non-Hodgkin lymphoma 5.8 5.5 5.8 5.8 6.2 6.6 6.5 6.9 7.0 6.8 7.5 7.4 7.7 7.9 8.0 2.7a)
Multiple myeloma 1.2 1.3 1.4 1.4 1.4 1.4 1.6 1.5 1.6 1.7 1.9 1.8 1.8 2.0 1.9 3.3a)
Leukemia 5.5 5.0 5.4 5.8 5.5 5.7 5.6 5.6 5.7 5.8 5.9 6.0 6.1 5.9 6.0 1.0a)
Other and ill-defined 17.9 16.5 16.8 16.5 18.5 18.3 19.3 18.9 20.4 19.8 20.0 19.9 20.9 20.3 20.5 1.6a)

APC was calculated using age-standardized incidence data based on the world standard population. APC, annual percentage change; CNS, central nervous system.

a) Significantly different from zero (p < 0.05),

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 7.
Trends in cancer incidence rates in women from 1999 to 2013 in Korea
Site/Type Year
 APCa)
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
All sites 161.1 157.4 169.0 174.6 184.6 193.9 208.1 216.7 232.5 249.9 263.9 275.5 290.3 292.9 281.8 5.1a)
Lip, oral cavity, and pharynx 1.6 2.4 1.7 1.7 1.7 1.9 1.9 1.8 1.9 1.9 1.8 2.2 2.1 2.0 2.2 1.3
Esophagus 0.6 0.6 0.6 0.5 0.6 0.5 0.4 0.5 0.5 0.5 0.4 0.4 0.4 0.5 0.4 –2.2a)
Stomach 26.7 25.2 26.2 26.3 25.9 24.7 26.8 25.1 24.8 25.1 25.8 25.4 25.3 23.7 22.4 –0.7a)
Colon and rectum 16.4 16.4 17.9 18.8 20.5 21.5 23.0 24.1 24.6 25.2 26.3 26.1 26.8 27.1 24.4 3.7a)
Liver 12.3 11.8 12.2 11.8 11.5 11.3 11.4 11.1 11.1 10.7 10.6 10.4 10.5 9.6 9.0 –1.8a)
Gallbladderb) 5.3 5.5 5.7 5.8 5.8 5.9 6.0 5.5 5.6 5.5 5.8 5.4 5.5 5.3 5.0 –0.5
Pancreas 4.0 4.0 4.0 4.2 4.4 4.5 4.7 4.7 4.8 4.9 4.9 5.0 5.1 5.4 5.2 2.2a)
Larynx 0.4 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 –7.0a)
Lung 12.4 12.5 12.3 12.6 12.4 13.0 13.5 14.0 14.0 14.2 14.2 14.8 15.4 15.1 14.9 1.7a)
Breast 20.9 20.9 24.7 27.2 27.9 29.4 32.1 33.3 35.7 37.3 38.8 40.8 44.1 44.9 45.7 5.9a)
Cervix uteri 16.3 15.1 15.8 14.8 14.2 13.2 12.4 12.2 11.1 11.5 10.7 10.9 10.2 9.6 9.5 –3.9a)
Corpus uteri 2.8 2.6 3.0 3.3 3.8 3.7 3.9 4.0 4.2 4.7 5.1 5.1 5.3 5.4 5.8 5.8a)
Ovary 5.0 4.8 4.8 5.0 5.2 5.2 5.5 5.4 5.9 5.6 5.4 5.9 5.8 6.1 6.0 1.7a)
Kidney 1.7 1.8 1.9 2.0 2.1 2.2 2.5 2.7 2.8 3.0 3.2 3.0 3.4 3.2 3.4 5.4a)
Bladder 1.6 1.6 1.7 1.7 1.8 1.7 1.7 1.6 1.7 1.6 1.6 1.5 1.5 1.4 1.4 –1.1a)
Brain and CNS 2.6 2.5 2.5 2.4 2.6 2.6 2.8 2.7 2.8 2.7 2.6 2.7 2.5 2.4 2.7 0.2
Thyroid 10.4 10.1 13.2 16.2 21.9 29.6 35.4 43.4 55.7 69.6 80.8 89.0 98.3 103.5 96.6 20.6a)
Hodgkin lymphoma 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.3 5.7a)
Non-Hodgkin lymphoma 3.4 3.2 3.4 3.5 4.0 4.1 4.4 4.4 4.4 4.8 5.2 5.2 5.6 5.7 5.6 4.4a)
Multiple myeloma 0.8 0.8 0.9 0.8 1.0 1.0 1.2 1.1 1.2 1.2 1.2 1.3 1.1 1.4 1.4 4.1a)
Leukemia 3.9 3.8 4.1 4.0 4.1 4.1 4.0 4.4 4.2 4.3 4.3 4.1 4.5 4.1 4.2 0.7a)
Other and ill-defined 11.8 11.5 11.8 11.5 12.9 13.2 13.9 14.2 14.9 15.0 14.9 15.8 16.2 15.9 15.6 2.7a)

APC was calculated using age-standardized incidence data based on the world standard population. APC, annual percentage change; CNS, central nervous system.

a) Significantly different from zero (p < 0.05),

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 8.
The five common sites of cancer incidence by age group and sex in Korea, 2013
Rank Age (yr)
0-14 15-34 35-64 ≥ 65
Male
 1 Leukemia (4.3) Thyroid (17.7) Stomach (88.3) Lung (449.4)
 2 Non-Hodgkin lymphoma (2.4) Leukemia (3.5) Colon and rectum (69.5) Stomach (396.3)
 3 Brain and CNS (2.0) Colon and rectum (3.2) Liver (62.4) Colon and rectum (333.4)
 4 Liver (0.4) Non-Hodgkin lymphoma (3.0) Thyroid (54.6) Prostate (289.3)
 5 Testis (0.4) Stomach (2.3) Lung (42.4) Liver (192.1)
Female
 1 Leukemia (3.4) Thyroid (71.7) Thyroid (228.2) Colon and rectum (176.5)
 2 Brain and CNS (1.9) Breast (10.6) Breast (123.9) Stomach (149.3)
 3 Non-Hodgkin lymphoma (1.1) Cervix uteri (5.5) Colon and rectum (40.8) Lung (126.6)
 4 Thyroid (0.6) Stomach (3.4) Stomach (38.8) Thyroid (92.7)
 5 Ovary (0.6) Ovary (3.1) Lung (21.7) Liver (72.5)

CNS, central nervous system.

Table 9.
Trends in the 5-year relative survival rates (%) by year of diagnosis from 1993 to 2013 in Korea
Site/Type Both sexes
 Male
 Female
1993-1995 1996-2000 2001-2005 2008-2013 Changea) 1993-1995 1996-2000 2001-2005 2008-2013 Changea) 1993-1995 1996-2000 2001-2005 2009-2013 Changea)
All sites 41.2 44.0 53.8 69.4 28.2 31.7 35.3 45.3 61.0 29.3 53.4 55.3 64.0 77.7 24.3
Lip, oral cavity, and pharynx 41.1 46.7 54.2 63.1 22.0 35.8 41.1 49.4 59.3 23.5 58.1 63.8 67.7 73.0 14.9
Esophagus 12.7 15.2 21.2 33.4 20.7 11.8 14.3 20.5 33.1 21.3 23.7 24.2 29.6 36.1 12.4
Stomach 42.8 46.6 57.7 73.1 30.3 43.0 46.9 58.4 73.9 30.9 42.6 46.0 56.4 71.5 28.9
Colon and rectum 54.8 58.0 66.6 75.6 20.8 55.3 59.0 68.5 77.5 22.2 54.2 56.8 64.2 72.6 18.4
Liver 10.7 13.2 20.2 31.4 20.7 9.9 12.9 20.2 31.6 21.7 13.6 14.2 20.4 30.8 17.2
Gallbladderb) 17.3 19.7 22.8 29.0 11.7 16.6 20.3 23.3 30.2 13.6 18.0 19.1 22.3 27.9 9.9
Pancreas 9.4 7.6 8.2 9.4 - 8.8 7.3 8.2 9.2 0.4 10.1 8.1 8.1 9.7 –0.4
Larynx 59.7 62.3 66.2 73.1 13.4 60.2 62.8 66.8 73.5 13.3 55.4 57.8 58.2 66.9 11.5
Lung 11.3 12.7 16.2 23.5 12.2 10.4 11.6 15.0 20.5 10.1 14.2 16.2 19.7 30.6 16.4
Breast 77.9 83.2 88.5 91.5 13.6 75.1 85.6 87.0 91.6 16.5 78.0 83.2 88.5 91.5 13.5
Cervix uteri 77.5 80.0 81.3 80.1 2.6 - - - - - 77.5 80.0 81.3 80.1 2.6
Corpus uteri 81.5 81.8 84.6 87.9 6.4 - - - - - 81.5 81.8 84.6 87.9 6.4
Ovary 58.7 58.9 61.4 62.0 3.3 - - - - - 58.7 58.9 61.4 62.0 3.3
Prostate 55.9 67.2 80.2 92.5 36.6 55.9 67.2 80.2 92.5 36.6 - - - - -
Testis 85.4 90.4 90.6 94.9 9.5 85.4 90.4 90.6 94.9 9.5 - - - - -
Kidney 62.0 66.1 73.4 80.8 18.8 60.8 64.4 72.8 80.5 19.7 64.5 69.7 74.5 81.6 17.1
Bladder 69.1 73.1 75.6 75.3 6.2 70.0 74.8 77.4 77.4 7.4 65.5 66.3 68.5 67.0 1.5
Brain and CNS 38.5 39.0 40.7 41.8 3.3 37.2 37.5 40.1 40.1 2.9 40.2 40.7 41.4 43.9 3.7
Thyroid 94.2 94.9 98.3 100.2 6.0 87.2 89.5 95.8 100.6 13.4 95.4 95.9 98.7 100.1 4.7
Hodgkin lymphoma 68.0 71.2 76.6 78.2 10.2 67.6 68.1 74.6 78.6 11.0 68.6 77.4 80.7 77.5 8.9
Non-Hodgkin lymphoma 46.6 50.8 60.0 68.4 21.8 45.3 48.9 58.1 66.6 21.3 48.7 53.5 62.4 70.5 21.8
Multiple myeloma 22.1 19.8 29.3 38.9 16.8 21.1 17.8 29.6 37.6 16.5 23.3 22.1 29.0 40.5 17.2
Leukemia 26.5 33.3 41.8 49.7 23.2 26.2 32.3 41.7 49.7 23.5 26.8 34.6 42.0 49.6 22.8
Other and ill-defined 42.1 45.9 55.9 68.1 26.0 37.4 42.4 52.2 64.6 27.2 47.4 50.0 60.0 71.7 24.3

CNS, central nervous system.

a) Percentage change in 5-year relative survival from 1993 to 1995 and 2009 to 2013,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 10.
Crude and age-standardized rates of cancer prevalence by sex on January 1, 2014 in Korea
Site/Type Crude prevalence rate per 100,000a)
 Age-standardized prevalence rate per 100,000b)
Both sexes Male Female Both sexes Male Female
All sites 2,709.8 2,387.1 3,032.6 1,772.4 1,683.6 1,944.3
Lip, oral cavity, and pharynx 36.7 49.3 24.0 24.3 34.7 15.3
Esophagus 16.0 29.0 3.0 9.9 20.0 1.7
Stomach 443.7 589.0 298.4 276.0 405.3 169.9
Colon and rectum 376.0 449.1 302.8 232.6 311.2 169.7
Liver 108.9 163.0 54.8 71.1 113.2 33.2
Gallbladderc) 31.7 32.4 31.0 19.0 22.3 16.5
Pancreas 15.3 16.6 14.1 9.7 11.6 8.2
Larynx 18.1 34.0 2.2 11.2 23.6 1.2
Lung 116.0 147.9 84.1 71.8 102.7 48.1
Breast 290.8 2.4 579.3 191.6 1.6 376.3
Cervix uteri 91.0 - 181.9 59.1 - 115.0
Corpus uteri 33.7 - 67.5 22.6 - 44.2
Ovary 30.4 - 60.8 21.6 - 42.7
Prostate 110.3 220.5 - 63.1 152.1 -
Testis 4.8 9.7 - 4.4 8.6 -
Kidney 57.5 77.6 37.4 38.2 54.5 23.9
Bladder 54.3 88.4 20.1 32.2 61.4 10.1
Brain and CNS 18.4 19.1 17.7 15.9 16.9 14.8
Thyroid 595.0 194.3 995.9 409.6 135.5 681.9
Hodgkin lymphoma 4.3 5.5 3.1 3.6 4.6 2.7
Non-Hodgkin lymphoma 58.0 62.5 53.6 41.9 47.7 36.7
Multiple myeloma 8.6 8.9 8.2 5.4 6.1 4.8
Leukemia 32.3 35.6 28.9 30.6 34.2 27.0
Other and ill-defined 158.0 152.3 163.8 107.2 115.8 100.2

CNS, central nervous system.

a) Crude prevalence rate: number of prevalent cases divided by the corresponding person-years of observation. Prevalent cases were defined as patients who were diagnosed between January 1, 1999 and December 31, 2013 and who were alive on January 1, 2014. Multiple primary cancer cases were counted multiple times,

b) Age-adjusted using the world standard population,

c) Includes the gallbladder and other/unspecified parts of the biliary tract.

TOOLS
Similar articles